

## **IMMUNE BASED THERAPIES FOR HIV INFECTION**

### **A TREATMENT INTERRUPTION TRIAL TESTING AN HIV VACCINE & DAILY LOW DOSE INTERLEUKIN 2 (IL2)**

#### **ENROLLMENT STILL IN PROGRESS**

- **PURPOSE OF TRIAL:** To determine whether HIV-specific canarypox vaccine immunizations and/or daily low dose IL2 therapy while viral replication is maximally suppressed with antiviral drugs will result in efficient immune control of viral replication subsequent to the interruption of antiviral drug therapy.
- **TRIAL DESIGN:** This is a three-step study. During step I, for 12 weeks volunteers will be randomly (i.e. by a flip of the coin) assigned to 1 of 4 immunotherapy groups. During step II, which will last 12 weeks, antiviral drug therapy will be interrupted and the concentration of HIV in the blood will be monitored once per week. During step III, antivirals will be interrupted for an additional 12 weeks, and the concentration of HIV in the blood will be monitored every other week.
- **ELIGIBILITY CRITERIA:** Volunteers must be 18 years of age, have a documented infection with HIV by blood tests, and have received Highly Active Anti-Retroviral Therapy (HAART) for at least 6 months. CD4+ T cell concentrations must be  $\geq 400$  cells/mL and the plasma HIV concentration must be  $< 50$  RNA molecules/mL on 2 successive occasions at least 14 days apart within 30 days of enrollment.
- **ANTICIPATED ENROLLMENT:** 92 volunteers
- **CONTACT:**

**Aquanette T. Sass  
Clinical Trials Coordinator  
Division of Immunology  
Weill Medical College of Cornell University  
Phone: 212-746-4361  
FAX: 212-746-8167  
EM: aqs2001@med.cornell.edu**